New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
11:07 EDTACOR, MYLAcorda sues Mylan over plans to duplicate Ampyra MS drug, Bloomberg says
News For ACOR;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
09:29 EDTACORAcorda Therapeutics management to meet with JPMorgan
Subscribe for More Information
07:26 EDTMYLInforma Business Information to hold a conference
Subscribe for More Information
September 24, 2014
16:22 EDTACOROn The Fly: Closing Wrap
Stocks on Wall Street were higher after a report showed that sales of new homes rose to their highest level in over six years in August. The volume and news flow were relatively light, which may be the case again tomorrow as many market participants celebrate the Jewish holiday of Rosh Hashanah. ECONOMIC EVENTS: In the U.S., new home sales rose 18.0% in August to a 504K unit rate, which was much higher than the expected 4.4% increase. COMPANY NEWS: Bed Bath & Beyond (BBBY) advanced $4.64, or 7.4%, to $67.33 after the home goods retailer last night reported second quarter earnings and revenue that surpassed analysts' consensus estimates. The better than expected report and rise in the stock comes a day after William Blair downgraded the stock yesterday morning... Citizen Financial (CFG), the U.S. retail bank unit of Royal Bank of Scotland (RBS), became the year's second largest IPO behind Alibaba (BABA) after 140M shares began trading on the NYSE this morning. The stock ended it first day up $1.58, or 7.35%, at $23.08, which was far cry from the advance seen by another of the day's new stock debuts. CyberArk (CYBR) priced 5.36M shares at $16.00, opened for trade at $25.00 and ended the day at $29.94, making for a rise of over 87% from its IPO pricing. MAJOR MOVERS: Among the notable gainers was Acorda Therapeutics (ACOR), which advanced $8.27, or 28.18%, to $37.62 after the company agreed to acquire Civitas Therapeutics for $525M in cash. Civitas, which was private, had been scheduled to come public via an IPO that was expected to happen later this week prior to the deal announcement. Also higher was Hasbro (HAS), which rose $2.01, or 3.8%, to $54.95 after striking a deal that gives the company global rights, excluding Japan, to develop dolls based on Disney's (DIS) princess characters, as well as Frozen, beginning in 2016. Mattel (MAT), which currently holds those rights, slid 40c, or 1.25%, to $31.67 in the wake of the news. Also lower were shares of Skechers (SKX), which fell $5.69, or 9.8%, to $52.40 after research firm SportscanInfo reported that the footwear maker's sales had fallen 3% last week. However, Sterne Agee recommended buying the stock on the weakness. INDEXES: The Dow rose 154.19, or 0.9%, to 17,210.06, the Nasdaq gained 46.53, or 1.03%, to 4,555.22, and the S&P 500 added 15.53, or 0.78%, to 1,998.30.
13:49 EDTACORAcorda Therapeutics price target raised to $65 from $52 at Cowen
Subscribe for More Information
12:29 EDTACOROn The Fly: Midday Wrap
Subscribe for More Information
10:38 EDTACORAcorda Therapeutics rallies on Civitas Therapeutics acquisition
Subscribe for More Information
09:52 EDTACORAlkermes expects to receive $59M in connection to Acorda-Civitas deal
Subscribe for More Information
09:05 EDTACOROn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTACORAcorda Therapeutics to host conference call
Subscribe for More Information
07:27 EDTACORAcorda acquires Civitas Therapeutics for $525M in cash
Subscribe for More Information
07:21 EDTACORAcorda Therapeutics trading halted, pending news
Subscribe for More Information
06:23 EDTMYLExperts see new tax rules not halting inversions, WSJ reports
Subscribe for More Information
September 23, 2014
10:54 EDTMYLStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
09:13 EDTMYLOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTMYLMylan shares defended at BofA/Merrill
Subscribe for More Information
08:53 EDTMYLInversion regulations look more onerous than expected, says FBR Capital
FBR Capital says the new regulations announced last night by the Treasury and IRS contain appear more onerous than expected. FBR points out the proposed changes remove the ability of inverting companies to make "hopscotch loans" between the foreign and domestic subsidiaries. The firm believes the regulations will not end the practice of inversions, and it still expects completion of already announced deals.
06:28 EDTMYLTreasury rules may put Mylan deal at risk, says BMO Capital
BMO Capital believes Treasury's new inversion rules may put the tax benefits of Mylan's (MYL) planned acquisition of Abbott's (ABT) established products business at risk. BMO also thinks the rules impact Salix's (SLXP) pending deal for Cosmo Pharmaceuticals, which it feels may help make a deal with Allergan (AGN) more likely.
05:56 EDTMYLTreasury, IRS announce plans to reduce inversion tax benefits
Subscribe for More Information
September 19, 2014
11:25 EDTMYLSenators bring bill requiring companies to settle before inverting
U.S. Senators Sherrod Brown and Dick Durbin announced new legislation requiring corporations to "Pay What You Owe Before You Go" – settling their U.S. tax bill before relocating to a foreign country. "Everyone knows that before you leave a restaurant you have to settle your tab," Brown said. "Corporations shouldn’t get to play by different rules. While it is critical that we reach a long-term solution that reforms our international corporate tax code by implementing a global minimum tax and reducing the statutory tax rate, this bill is an immediate, commonsense measure to ensure businesses settle up before leaving the U.S." Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN).
September 17, 2014
11:01 EDTMYLActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use